TITLE

Vernakalant: A novel agent for the termination of atrial fibrillation

AUTHOR(S)
Finnin, Miki
PUB. DATE
July 2010
SOURCE
American Journal of Health-System Pharmacy;7/15/2010, Vol. 67 Issue 14, p1157
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The pharmacology, pharmacokinetics, safety, clinical efficacy, and role of intravenous vernakalant hydrochloride for the rapid conversion of atrial fibrillation (AF) to normal sinus rhythm are reviewed. Summary. Vernakalant, currently being evaluated by the Food and Drug Administration (FDA), for the termination of atrial fibrillation, differs in pharmacology from other antiarrhythmics; it achieves action potential interference through blockade of sodium and potassium currents. Vernakalant's actions appear to be directed at relatively atrial-selective potassium currents, which result in lengthening of the atrial action potential and prolongation of the atrial action potential plateau, while not significantly affecting the Q-T interval or the ventricular effective refractory period. As a result, the proarrhythmic effects observed with all other agents approved by FDA for the treatment of AF are eliminated. In clinical trials of vernakalant versus placebo, a statistically significant number of patients converted to normal sinus rhythm after receiving vernakalant. For patients with atrial fibrillation continuing for 3-72 hours, the median time to conversion was between 8 and 14 minutes, with 79% of those who converted remaining in sinus rhythm at 24 hours. Conclusion. Intravenous vernakalant, a novel, relatively atrial-selective antiarrhythmic agent, appears to offer an effective and safe approach to the rapid conversion of recent-onset AF to normal sinus rhythm.
ACCESSION #
51870149

 

Related Articles

  • Atrial fibrillation: New understanding, new tools.  // Patient Care;1/30/2002, Vol. 36 Issue 2, p30 

    Discusses the treatment for atrial fibrillation (AF). Treatment goals for AF; Constant threat in patients with AF; Drugs most often use for ventricular rate control. INSET: Office management of patients with AF.

  • The management of atrial fibrillation in elderly patients. Hampton, John R. // Age & Ageing;May99, Vol. 28 Issue 3, p248 

    Describes atrial fibrillation. Causes; Drug therapy for atrial fibrillation; Stroke association with atrial fibrillation.

  • First robotic heart procedure in Michigan.  // Medical Device Daily;3/8/2011, Vol. 15 Issue 45, p8 

    The article reports on the first minimally invasive robotic procedure conducted by doctors at Beaumont Hospital to correct atrial fibrillation.

  • TEST QUESTIONS.  // Drug Topics;Aug2014, Vol. 158 Issue 8, p50 

    A quiz concerning the use of different types of drugs in the treatment of atrial fibrillation.

  • KEEP TICKING. Karpa, Kelly Dowhower // Drug Topics;10/1/2001, Vol. 145 Issue 19, p32 

    Presents guidelines for managing patients with different types of atrial fibrillation. Nature and symptoms of the disease; Algorithms for pharmacologic interventions; Benefits of the guidelines.

  • Atrial fibrillation treatment focus shifts from rhythm to rate control. Glatter, Kathryn; Herweg, Bengt; Jaffe, Charles // Patient Care;Jan2006, Vol. 40 Issue 1, p58 

    The article presents a meta-analysis of randomized clinical trials of initial therapy for atrial fibrillation (AF) comparing rhythm and rate control. It lists the reason against the use of rhythm control as first-line strategy in patients with persistent AF. It details clinical considerations...

  • Ablation Frontiers gets FDA nod to hike trial enrollment. Amanda, Pedersen // Medical Device Daily;1/22/2008, Vol. 12 Issue 14, p1 

    The article reports on the approval received by Ablation Frontiers from the U.S. Food and Drug Administration (FDA) to extend U.S. enrollment in its clinical trial for interventional treatment of atrial fibrillation. According to Ablation, its Tailored Treatment of Permanent Atrial Fibrillation...

  • Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation. Klein, Allan L.; Grimm, Richard A.; Murray, R. Daniel; Apperson-Hansen, Carolyn; Asinger, Richard W.; Black, Ian W.; Davidoff, Ravin; Erbel, Raimund; Halperin, Jonathan L.; Orsinelli, David A.; Porter, Thomas R.; Stoddard, Marcus F. // New England Journal of Medicine;05/10/2001, Vol. 344 Issue 19, p1411 

    Background: The conventional treatment strategy for patients with atrial fibrillation who are to undergo electrical cardioversion is to prescribe warfarin for anticoagulation for three weeks before cardioversion. It has been proposed that if transesophageal echocardiography reveals no atrial...

  • Antithrombotic treatment before stroke onset and stroke severity in patients with atrial fibrillation and first-ever ischemic stroke: An observational study. Po, Helen L.; Ya-Ju Lin // Neurology Asia;Jun2010, Vol. 15 Issue 1, p11 

    Background and Objectives: Atrial fibrillation (AF) is an important, independent risk factor for stroke. The value of antithrombotic therapy to prevent stroke is well established in numerous randomized controlled trials. The objectives of this study were to determine the rate and the factors...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics